Only a few drugmakers even try to fight superbugs — a growing threat

  23 January 2020

Progress in tackling drug-resistant infections isn’t keeping pace with the rising threat, according to the latest Antimicrobial Resistance Benchmark, published Tuesday by the Access to Medicine Foundation. The pipeline of new antibiotics in advanced tests remains too small, the nonprofit found.

News from the field is grim as low profits discourage investment in crucial antibiotics. Since the group’s last report in 2018, two major players, Novartis and Sanofi, have retreated from antibiotic research as the pharma industry shifts toward lucrative areas such as cancer. And two smaller drug developers, Achaogen Inc. and Melinta Therapeutics, have filed for bankruptcy.

Further reading: Los Angeles Times
Author(s): James Paton
Healthy Patients   Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!